Molecular Templates, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
  • Technology
    • Overview
    • Posters
  • Pipeline
    • Overview
    • MT-3724
    • MT-5111
    • TAK-169
  • Clinical Trials
    • Overview
    • MT-3724 With Lenalidomide for Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma Active, not recruiting
    • MT-3724 for Relapsed or Refractory DLBCL Active, not recruiting
    • MT-3724 With Gemcitabine and Oxaliplatin for Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma Active, not recruiting
    • MT-5111 in HER2-positive Solid Tumors Recruiting
    • TAK-169 for Relapsed or Refractory Multiple Myeloma (RRMM) Recruiting
  • News & Media
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
    • Email Alerts
  • Contact
  • Careers

Press Releases

News & Media

News & Media

  • Press Releases
  • Presentations
  • Events

Molecular Templates Announces FDA Acceptance of IND Application for MT-6402, a PD-L1-Targeted Engineered Toxin Body Enabled with Proprietary Antigen Seeding Technology

Jan 19, 2021 8:00am EST

Molecular Templates, Inc. Provides Update on MT-5111 Phase 1 Study

Dec 21, 2020 4:30pm EST

Molecular Templates to Participate in Upcoming Virtual Investor Conferences

Nov 16, 2020 4:30pm EST

Molecular Templates, Inc. Reports Third Quarter 2020 Financial Results and Provides a Corporate Update

Nov 05, 2020 4:30pm EST

Molecular Templates to Participate in September Virtual Investor Conferences

Sep 03, 2020 8:00am EDT

Molecular Templates, Inc. Reports Second Quarter 2020 Financial Results

Aug 06, 2020 4:30pm EDT

Molecular Templates, Inc. Raises $43 Million in Gross Proceeds Through Its At-the-Market Facility

Jul 20, 2020 4:30pm EDT

Molecular Templates’ Presentations at the American Association of Cancer Research (AACR) Annual Meeting 2020 Highlight Evolution of ETB Platform

Jun 22, 2020 7:30am EDT

Molecular Templates, Inc. Announces $45 Million Debt Financing From K2 HealthVentures

May 22, 2020 8:00am EDT

New Data on Molecular Templates’ Engineered Toxin Bodies to be Presented at the American Association of Cancer Research (AACR) Virtual Annual Meeting II

May 15, 2020 7:00am EDT
RSS
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
Next
© 2021 Molecular Templates, Inc. All Rights Reserved.
Twitter Linkedin
Privacy Policy Disclaimer Terms of Use Sitemap